1-deprenyl 10 mg daily, given without levodopa, has been shown to increase cerebral dopamine levels, with minimal effect on other transmitter
Dopamine is rapidly catabolised in the brain by monoamine oxidase (MAO) and catechol-Omethyl transferase (COMT). ' Despite frequent oral doses of levodopa, symptom fluctuation is common in Parkinsonian patients after two to three years of levodopa treatment, and often becomes increasingly severe and disabling. ' 3 Retarding the breakdown of dopamine by the inhibition of either MAO or COMT might prolong the anti-Parkinsonian effect of each separate dose of levodopa and reduce symptom fluctuations.4 5 However, the combination of levodopa with most available MAO Full blood count, ESR, serum biochemistry, ECG, pulse and lying and standing blood pressure was noted before the trial, and after each two-week treatment period. In six patients 24-hour urine output was collected whilst they were taking deprenyl (see below). Assessment of results At the end of the trial both the patient and the observer compared the two treatment periods. The patient was asked which period was preferable in terms of severity of symptom fluctuation and overall mobility, while taking into account any increase in dyskinesia or the emergence of any side-effects. The observer made a similar comparison on the basis of his weekly assessments, and taking note of comments from the patient's family.
For further assessment, mean hourly mobility and dyskinesia scores, the mean daily number of freezing episodes, and the mean daily levodopa dosage were all determined from the patient's own records. The final week of the placebo period and the final week of the deprenyl period are compared in the Results section. Studies of deprenyl metabolism (P Jenner and B Testa) Urine levels of deprenyl, methylamphetamine and amphetamine were determined by gasliquid chromatography according to a modification of the method of Campbell,24 using p-hloram- 
Metabolism of deprenyl
In the six patients studied, the 24-hour excretion of amphetamine ranged from 0-45 to 1-63 mg (mean 1-10 mg) and of methylamphetamine from 1-45 to 4-03 mg (mean 2-47 mg). Urinary pH was 5-70 or higher in all cases, and was thus more alkaline than that required for maximal amphetamiine excretion. Examination of the enantiomeric composition of the amphetamine and methylamphetamine revealed in each case predominance of the R(-)-isomer. Less than 6-5% of the S(+)-isomer was present in any of the samples, and this was attributed to the enantiomeric impurity of the admninistered 1-deprenyl.
No unchanged deprenyl was detected in the urine of any of the patients. These results are substantially in agreement with those of Reynolds et al. 22 Side-effects and toxicity The increase in dyskinesias accompanying deprenyl therapy has been noted above. One patient had slight epigastric discomfort after each dose of deprenyl. No other side-effects attributable to deprenyl were noted during the trial. Pulse rate, blood pressure, blood count, erythrocyte sedimentation rate, serum biochemistry and the electrocardiogram remained unchanged in all patients taking deprenyl.
Discussion
Half the patients with dose-related response swings in this study showed improvement in mean hourly mobility scores and prolongation of levodopa action, accompanied by increased dyskinesia but little change in levodopa dosage. The majority of patients in this group preferred not to reduce the dose of levodopa, despite the exacerbation of dyskinesia, as they found that such a reduction impaired mobility. Only one of the 10 patients in this group did not express a preference for deprenyl rather than placebo.
In contrast, only two of seven patients in the random group preferred deprenyl, and the doctor's assessment was in agreement with this. This occurred despite slight improvements in mean hourly mobility scores in this random group, and only a minor increase in dyskinesia. The reason for this can be inferred from figures 1 and 3. In the end-of-dose group the total duration of periods of severe disability was reduced by deprenyl, while in the random group there was an increase in such periods. Since the overall mean hourly mobility score in the random group generally showed an improvement, it follows that there were more severe swings from "good" to "bad" periods in these patients.
No serious side-effects were encountered during the trial and no systemic toxicity was observed. Other studies14-20 have reported much more frequent side-effects, including nausea, postural hypotension, dryness of the mouth, anxiety, insomnia and hallucinations. These trials were all of longer duration than the present one, lasting from one month to two years, and a possible accumulation of deprenyl during prolonged treatment26 may be responsible for increased toxicity, although this theory is not supported by more recent work.27 Further reduction in levodopa dosage would also be anticipated during a longer trial.
The mechanism of "on-off" effects remains poorly understood. Although variations in plasma dopa and cerebral dopamine levels may be important in patients with dose-related fluctuations, they do not explain apparently random swings from akinesia to dyskinesia. Changes in dopamine receptor sensitivity during chronic levodopa therapy have been proposed, but evidence for this in man is limited.28 29 The mode of action of deprenyl is complex. As far as the drug's anti-Parkinsonian activity is concerned, it is uncertain whether its role as a selective MAO inhibitor is of greater importance than effects on dopamine release and re-uptake,'213 which may be due to metabolites of deprenyl.22 Furthermore, there is no doubt that there is substantial conversion of deprenyl to amphetamine and methylamphetamine, as this study confirms. 22 Indeed, we were unable to detect unchanged deprenyl in the urine of any patient. As expected, the conversion occurs with retention of configuration, the R-(-)-isomers of the amphetamines being excreted predomlinantly. This isomer of amphetamine has a minor antiParkinsonian effect. 30 The site of interconversion is probably the liver, but any amphetamine formed there will readily cross the blood-brain barrier.
Despite these uncertainties, deprenyl appears to be a useful adjuvant in the management of dose-related response swings in patients already on optimal levodopa therapy. Subsequent experience suggests that the benefits of a smoother response to levodopa obtained in such patients by adding deprenyl may continue for many months. However, uncontrollable, random oscillations appear in about 50% of those treated with this combination for six months or more.
Although the drug is not generally available, we believe that deprenyl has a definite role in the treatment of Parkinson's disease at this time. In patients who develop disabling dose-related response swings we would advocate firstly a readjustment of the tinming of levodopa dosage, then the addition of deprenyl, which is simple to administer and lacks serious toxicity. If these measures fail, the addition or substitution of a directly-acting dopamine agonist, such as bromocriptine, then might be considered. 
